← United States · Coverage record
US · SEC FORM 4
Alamar Biosciences, Inc.
ALMR · Nasdaq · CIK 0002104204 · Healthcare · Medical Devices
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
2 Form 4 transaction lines observed in the same window
0 sales · 2 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Latest recorded score
- 61.1
- 61.1
- 61.1
- 61.1
- 61.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -9.0%
- 3M
- -7.8%
- 6M
- —
- 12M
- —
Volatility & liquidity
- Volatility
- 86.0%
- Beta
- —
- Avg daily value
- USD 10.7M
Valuation
- Market cap
- USD 1.8B
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Medical Devices
Market data
Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 2,810,938
- Previous report
- 2,122,340
- Avg daily volume
- 661,422
- Days to cover
- 4.2
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-04-20 | Naclerio Nicholas | Purchase (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | Purchase (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC filing ↗ |
Form 4 evidence
46 transaction lines in the latest 365-day window; 46 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Brottem John L. | Award / grant (A) | Common Stock | 29,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-01 | RAGUSA ROBERT P | Award / grant (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Common Stock | 10,594,547 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (28 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Brottem John L. | Award / grant (A) | Common Stock | 29,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-01 | RAGUSA ROBERT P | Award / grant (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Common Stock | 10,594,547 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Class B Common Stock | 10,594,547 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | C (C) | Class B Common Stock | 10,594,547 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | White Timothy Ogden | J (J) | Common Stock | 454,583 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | White Timothy Ogden | J (J) | Class B Common Stock | 454,583 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | White Timothy Ogden | Award / grant (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | Purchase (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | J (J) | Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | J (J) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | C (C) | Common Stock | 617,802 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | C (C) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Naclerio Nicholas | Award / grant (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | McAnear Justin J. | Award / grant (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Luo Yuling | J (J) | Common Stock | 3,088,217 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Luo Yuling | J (J) | Class B Common Stock | 3,088,217 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Luo Yuling | C (C) | Class B Common Stock | 2,975,166 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Luo Yuling | Award / grant (A) | Common Stock | 76,509 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | Purchase (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | J (J) | Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | J (J) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | C (C) | Common Stock | 617,802 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | C (C) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Chen Shiping | J (J) | Common Stock | 722,885 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Chen Shiping | J (J) | Class B Common Stock | 722,885 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Chen Shiping | C (C) | Class B Common Stock | 393,364 | USD — | USD — | SEC filing ↗ |
| 2026-04-20 | Chen Shiping | Award / grant (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ALMR |
| CIK | 0002104204 |
| Sector | Healthcare |
| Industry | Medical Devices Yahoo Finance |
| SEC SIC | 3826 Laboratory Analytical Instruments |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 46 transaction lines from 2026-04-20 to 2026-09-14 2 P purchase lines · 0 S sale lines · 44 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.